California Public Employees Retirement System Trims Stock Holdings in Thermo Fisher Scientific Inc. $TMO

California Public Employees Retirement System reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the first quarter, Holdings Channel.com reports. The fund owned 696,589 shares of the medical research company’s stock after selling 30,305 shares during the quarter. California Public Employees Retirement System’s holdings in Thermo Fisher Scientific were worth $342,394,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Quadrant Private Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 32.4% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 1,830 shares of the medical research company’s stock valued at $900,000 after buying an additional 448 shares in the last quarter. Watershed Asset Management L.L.C. grew its stake in Thermo Fisher Scientific by 29.6% in the 1st quarter. Watershed Asset Management L.L.C. now owns 7,000 shares of the medical research company’s stock worth $3,441,000 after acquiring an additional 1,600 shares in the last quarter. Heartland Bank & Trust Co increased its position in shares of Thermo Fisher Scientific by 29.9% during the first quarter. Heartland Bank & Trust Co now owns 1,928 shares of the medical research company’s stock worth $948,000 after acquiring an additional 444 shares during the period. Atlas Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 804.1% during the first quarter. Atlas Wealth LLC now owns 36,880 shares of the medical research company’s stock valued at $18,128,000 after acquiring an additional 32,801 shares in the last quarter. Finally, Cornerstone Planning Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 22.6% in the first quarter. Cornerstone Planning Group LLC now owns 239 shares of the medical research company’s stock valued at $111,000 after purchasing an additional 44 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on TMO. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research note on Thursday, May 14th. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price on the stock. Finally, Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $602.14.

Thermo Fisher Scientific Stock Down 2.0%

Thermo Fisher Scientific stock opened at $532.17 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $403.36 and a 1-year high of $643.99. The business has a fifty day moving average price of $484.57 and a 200-day moving average price of $514.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a market capitalization of $197.77 billion, a price-to-earnings ratio of 29.26, a PEG ratio of 2.41 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.